Brief: Bergenbio Announces Data From Bemcentinib Trial In Mesothelioma Presented At Asco
05/06/2023 21:12
June 5 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO ANNOUNCES DATA FROM BEMCENTINIB TRIAL IN
MESOTHELIOMA
PRESENTED AT ASCO
* INVESTIGATOR-LED PHASE IIA STUDY MET ITS PRIMARY ENDPOINT
OF
DISEASE CONTROL RATE AT 12 WEEKS
* COMBINATION OF BEMCENTINIB AND PEMBROLIZUMAB WAS GENERALLY
SAFE
AND WELL-TOLERATED
Source text for Eikon: ID:nObiy1FQSa
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee